For the fifth time since 1997, GlaxoSmithKline will be reducing the prices of its anti-HIV drugs for developing countries all over the world. The biggest reduction will be on the drug Ziagen, which will have around 40 percent shaved off its original price, and which the World Health Organization has identified as a first- and second-line treatment for HIV. “These prices will take effect immediately for public sector customers and not-for-profit organizations in the least developed countries and sub-Saharan Africa (as well as other eligible countries),” the pharmaceutical company said in a statement. Over 33 million people worldwide have contracted HIV, a incurable and fatal infection whose effects have been most pronounced in sub-Saharan Africa and other poor states.
Source: Glaxo cuts HIV drug prices for poor countries (Reuters)